MSN Lab signs licensing pact with DRDO for anti-Covid drug 2 DG

Hyderabad: MSN Laboratories Pvt Ltd (MSN) on Friday announced that it has entered into a license agreement with the Defence Research & Development Organisation (DRDO) for the manufacturing, distribution and marketing of Covid-19 drug 2-Deoxy-D-Glucose (2-DG) in India.

Developed by DRDO, 2-DG has been granted permission by Drug Controller General of India (DCGI) for emergency use of this drug as adjunct therapy in moderate to severe Covid-19 patients.

The company said it will be launching the drug as a twice a day product in sachet form under the brand name MSN 2D in strength of 2.34 g.

The company said while it has already launched anti-viral medications like Oseltamivir and anti Covid drug like Favipiravir and Baricitinib as well as antifungal medication like Posaconazole in the fight against Covid-19, it is also conducting clinical trials with investigational drugs like Aviptadil on severe hospitalized patients and with Molnupiravir on mild and moderate Covid patients.

MSN Group is the fastest growing research based pharmaceutical company headquartered in India. Founded in 2003 with a mission to make health care affordable, the pharma company has nine API and five finished dosage facilities in Hyderabad and the US.